From Wikipedia, the free encyclopedia
Jump to: navigation, search
Systematic (IUPAC) name
Clinical data
Routes of
CAS Registry Number 129580-63-8 YesY
ATC code L01XA04
PubChem CID: 123974
UNII 8D7B37T28G YesY
ChEBI CHEBI:85609 YesY
Synonyms BMY 45594
BMS 182751
(OC-6-43)-bis(acetato)amminedichlorocyclohexylamine platinum(IV)
Chemical data
Formula C10H22Cl2N2O4Pt
Molecular mass 500.277 g/mol
 YesY (what is this?)  (verify)

Satraplatin (INN, codenamed JM216) is a platinum-based antineoplastic agent that is under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U.S. Food and Drug Administration.[1] First mentioned in the medical literature in 1993,[2] satraplatin is the first orally active platinum-based chemotherapeutic drug;[3] other available platinum analogues—cisplatin, carboplatin, and oxaliplatin—must be given intravenously.

It is made available in the United States jointly by Spectrum Pharmaceuticals and GPC Biotech under the name SPERA (SatraPlatin Expanded Rapid Access).

The drug has also been used in the treatment of lung and ovarian cancers. The proposed mode of action is that the compound binds to the DNA of cancer cells rendering them incapable of dividing.[4]


  1. ^ Wheate, Nial J.; Walker, Shonagh; Craig, Gemma E.; Oun, Rabbab (2010). "The status of platinum anticancer drugs in the clinic and in clinical trials". Dalton Transactions 39 (35): 8113–27. doi:10.1039/C0DT00292E. PMID 20593091. 
  2. ^ Kelland LR, Abel G, McKeage MJ, et al. (1993). "Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug" (PDF). Cancer Res 53 (11): 2581–6. PMID 8388318. 
  3. ^ Choy H, Park C, Yao M (2008). "Current status and future prospects for satraplatin, an oral platinum analogue". Clin Cancer Res 14 (6): 1633–8. doi:10.1158/1078-0432.CCR-07-2176. PMID 18347164. 
  4. ^ Satraplatin — Spectrum Pharmaceuticals